"Designing Growth Strategies is in our DNA"

Cardiac Biomarkers Market Size, Share & Industry Analysis, By Indication (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, and Others), By Biomarker (Troponin, Creatine kinase-MB (CK-MB), B-type Natriuretic Peptide (BNP), Myoglobin, and Others), By End User (Hospitals, and Specialty Clinics), and Regional Forecast, 2020-2032

Last Updated: February 03, 2025 | Format: PDF | Report ID: FBI101233

 


To get information on various segments, share your queries with us

 ATTRIBUTE

 DETAILS

Study Period

  2016-2027

Base Year

  2019

Forecast Period

  2020-2027

Historical Period

  2016-2018

Unit

  Value (USD billion)

Segmentation

By Indication

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Others

By Biomarker

  • Troponin
  • Creatine Kinase-MB (CK-MB)
  • B-type Natriuretic Peptide (BNP)
  • Myoglobin
  • Others

By End User

  • Hospitals
  • Specialty Clinics

By Geography

  • North America (the U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
  • Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)
  • Latin America (Brazil, Mexico, and the Rest of Latin America)
  • The Middle East & Africa (South Africa, GCC and the Rest of Middle East & Africa)
  • REPORT UPDATE
    IN PROCESS
  • 2019-2032
    (In Process)
  • 2023
    (In Process)
Multi-report Purchase Plan
    A Customized Plan Will be Created Based on the number of reports you wish to purchase
Healthcare Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann